Wieduwilt, Matthew J. http://orcid.org/0000-0002-5414-9228
Stock, Wendy
Advani, Anjali http://orcid.org/0000-0003-0015-5902
Luger, Selina http://orcid.org/0000-0003-3364-4366
Larson, Richard A. http://orcid.org/0000-0001-9168-3203
Tallman, Martin
Appelbaum, Frederick
Zhang, Mei-Jie
Bo-Subait, Khalid
Wang, Hai-Lin
Bhatt, Vijaya Raj http://orcid.org/0000-0003-2513-0533
Dholaria, Bhagirathbhai http://orcid.org/0000-0003-2371-3655
Eapen, Mary
Hamadani, Mehdi http://orcid.org/0000-0001-5372-510X
Jamy, Omer
Prestidge, Tim http://orcid.org/0000-0003-4078-5001
Pulsipher, Michael http://orcid.org/0000-0003-3030-8420
Ritchie, David
Rizzieri, David
Sharma, Akshay http://orcid.org/0000-0003-3281-2081
Barba, Pere http://orcid.org/0000-0003-1038-5197
Sandmaier, Brenda M. http://orcid.org/0000-0002-9767-9739
de Lima, Marcos http://orcid.org/0000-0002-8568-4522
Kebriaei, Partow http://orcid.org/0000-0002-8607-9404
Litzow, Mark http://orcid.org/0000-0002-9816-6302
Saber, Wael
Weisdorf, Daniel http://orcid.org/0000-0001-8078-8579
Article History
Received: 17 September 2020
Revised: 28 January 2021
Accepted: 25 February 2021
First Online: 30 March 2021
Change Date: 4 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01303-4
Compliance with ethical standards
:
: PBP reports Advisory from CELGENE-BMS, Advisory from NOVARTIS, Advisory from KITE-GILEAD, Advisory from AMGEN, outside the submitted work. MT reports personal fees from Miami Cancer Symposium, personal fees from NCCN, personal fees from UC Davis, personal fees from Mayo Clinic, personal fees from American Society of Hematology, personal fees from New Orleans, personal fees from ASCO, personal fees from Vanderbilt University, personal fees from Targeted Oncology, personal fees from Indy, personal fees from Emirates Hematology Society, personal fees from German AML Cooperative Group, personal fees from Penn State Cancer Institute, personal fees from prIME Oncology, personal fees from HammersmithHospital, personal fees from EHA Congress, personal fees from National Institute of Health/National Heart, Lung and Blood Institute, personal fees from International Symposium, personal fees from National Comprehensive Cancer Network, personal fees from TRM Oncology, personal fees from Medscape, personal fees from Sylvester Comprehensive Cancer Center, personal fees from ESH, personal fees from Chinese Medical Association, personal fees from Rambam Health Care Campus and Shaare Zedek Medical Center, personal fees from AMEH, grants from AbbVie, grants from Cellerant, grants from Orsenix, grants from ADC Therapeutics, grants from Biosight, grants from Glycomimetics, grants from Rafael Pharmaceuticals, grants from Amgen, Advisory Board from AbbVie, Advisory Board from BioLineRx, Advisory Board from Daiichi-Sankyo, Advisory Board from Orsenix, Advisory Board from KAHR, Advisory Board from Rigel, Advisory Board from Nohla, Advisory Board from Delta Fly Pharma, Advisory Board from Tetraphase, Advisory Board from Oncolyze, Advisory Board from Jazz Pharma, Advisory Board from Roche, Advisory Board from Biosight, Advisory Board from Novartis, Royalties from UpToDate, outside the submitted work. SL reports honoraria from Daiichi-Sankyo, Pfizer, Bristol-Myers Squibb, Acceleron, Agios, Loxo Oncology. SL reports institutional research support from Onconova, Kura, Hoffman La Roche, Ariad, Biosight, outside the submitted work. DRit reports grants from Amgen Australia, grants from Takeda Pharmaceuticals, grants from BMS Australia, outside the submitted work. DRiz reports personal fees from Amgen, personal fees from Kite, personal fees from AROG, personal fees from Pharmacyclics, personal fees from Seattle Genetics, personal fees from Pfizer, personal fees from Novartis, personal fees from Sanofi-Aventis, personal fees from Incyte, personal fees from Gilead, personal fees from Jazz, consulting and presentation to FDA for biosimilar review from Celltron/Teva, consulting and Advisory Board from Mustang, consulting from Bayer, research support, consultant, Speakers Bureau, Advisory Board from Stemline, personal fees from Celegene, outside the submitted work. MdL reports grants from Pfizer, grants from Celgene, personal fees from Kadmon, personal fees from Pfizer, personal fees from Incyte, personal fees from BMS, outside the submitted work. RAL reports personal fees from Amgen, personal fees from AstraZeneca, personal fees from Agios, personal fees from CVS/Caremark, personal fees and clinical trials from Celgene, personal fees from Delta Fly, personal fees from Epizyme, personal fees and clinical trials from Novartis, personal fees from Takeda, clinical trials from Astellas, clinical trials from Cellectis, clinical trials from Daiichi-Sankyo, clinical trials from Rafael Pharmaceuticals, clinical trials from Forty Seven, outside the submitted work. DW reports grants from Incyte, personal fees from FATE Therapeutics, outside the submitted work. AA reports grants from Novartis, grants from Abbvie, grants from Macrogenics, grants and personal fees from Glycomimetics, grants and personal fees from Pfizer, grants and personal fees from Amgen, personal fees from Seattle Genetics, personal fees from Kite Pharmaceuticals, during the conduct of the study. MP reports personal fees from Novartis, grants and personal fees from Miltenyi, grants from Adaptive, personal fees from Mesoblast, personal fees from Jasper, personal fees from Bellicum, outside the submitted work. WSt reports grants from NCI, during the conduct of the study. AS reports salary support from Vertex Pharmaceuticals/CRISPR Therapeutics paid to the institution, non-financial support from Novartis, non-financial support from Magenta Therapeutics, outside the submitted work. He is the principal investigator of a clinical trial for gene therapy of sickle cell disease sponsored by Vertex Pharmaceuticals/CRISPR Therapeutics. The sponsor provides funding for the clinical trial, which includes salary support paid to his institution. This is not related in any way to this work product. He also has research collaboration with Novartis, Magenta Therapeutics, and Bluebird Bio for which he is not financially compensated in any way. VRB reports personal fees from Agios, grants and personal fees from Incyte, personal fees from Takeda, personal fees from Partner Therapeutics, personal fees from Omeros, grants and personal fees from Abbvie, grants from Jazz, grants from National Marrow Donor Program, drug support for a trial from Oncoceutics, personal fees from Partnership for health analytic research, LLC, grants, personal fees and educational grant to institution from Pfizer, personal fees from CSL Behring, grants from Tolero Pharmaceuticals, personal fees from Rigel Pharmaceuticals, educational grant to institution from Novartis, outside the submitted work. BD reports Research support from Jenssen, Takeda, and Angiocrine as well as consultancy from Celgene/Juno. MJW, FA, M-JZ, KB-S, H-LW, ME, MH, OJ, TP, BMS, ML, and WS declare no competing financial interests.